Inclusion Criteria:

          -  Patients with histologically or cytologically confirmed diagnosis of locally advanced
             or metastatic solid tumors

          -  Patients must have activating genomic alterations in ALK or ROS1 (mutations, fusions
             or amplifications) by any validated Clinical Laboratory Improvement Act
             (CLIA)-certified molecular testing (fluorescence in situ hybridization [FISH],
             polymerase chain reaction [PCR] or next-generation sequencing [NGS] data are
             acceptable); CLIA validated results from other institutions and commercial diagnostic
             labs (e.g. Foundation Medicine) are also acceptable

          -  Patients with progressive disease on any previous therapy including crizotinib and
             other ALK tyrosine kinase inhibitors (TKIs), chemotherapy or immunotherapy

          -  Patients with locally advanced or metastatic solid tumors who have received no
             previous therapy of any kind (i.e. first-line therapy) are eligible

          -  Patients with brain metastases or metastases elsewhere within the central nervous
             system (CNS) are eligible for study; patients must be neurologically stable and
             asymptomatic

          -  Patients with tumor suitable for biopsy (as assessed by trained specialists in
             interventional radiology) and medically fit to undergo a biopsy or surgical procedure
             will have mandatory pre-treatment tumor biopsy or sampling; however, if patients do
             not have a tumor suitable for biopsy but have another tissue (preferably progressive
             metastatic site) available for molecular evaluation this will be acceptable

          -  Patients with solid tumors must have at least 1 measurable lesion per Response
             Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1; Note: previously
             irradiated lesions may not be used for target lesions; unless there is unambiguous
             radiological progression after radiotherapy; brain lesions may not be used as target
             lesions if they were: 1) previously treated with whole brain radiation therapy (WBRT)
             within 3 months, or 2) previously treated by stereotactic radiosurgery (SRS) or
             surgical resection

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2

          -  Life expectancy of greater than 3 months

          -  Patients with multiple malignancies remain eligible

          -  Patients with an inherited cancer syndrome or a medical/family history suggestive of
             an inherited cancer syndrome remain eligible

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and
             through 4 months after the end of treatment; for women of childbearing potential, a
             negative pregnancy test must be documented prior to registration

          -  Absolute neutrophil count >= 1,500/mcL

          -  Hemoglobin >= 10 g/dL

          -  Platelet count >= 75,000/mcL

          -  Total bilirubin =< 1.5 x upper limit of normal (ULN), unless due to Gilbert?s syndrome
             (< 5 if metastatic involvement of the liver)

          -  Serum lipase =< 1.5 x ULN

          -  Serum amylase =< 1.5 x ULN

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x
             institutional ULN

          -  Left ventricular ejection fraction (LVEF) >= 50% by echocardiogram or multi-gated
             acquisition (MUGA)

          -  Normal QT interval on screening electrocardiogram (ECG), defined as QT interval
             corrected of =< 450 ms in males or =< 470 ms in females

          -  Serum creatinine =< 1.5 mg/dL OR calculated creatinine clearance (Cockroft-Gault
             formula) >= 60 mL/min OR 24-hour urine creatinine clearance >= 60 mL/min

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients with hematological malignancies

          -  Patients with ALK positive (+) lung cancer

          -  Major surgery (e.g. thoracic, abdominal, vascular, neurosurgery) within 30 days prior
             to registration on study

          -  Pregnant women or mothers who are breastfeeding

          -  Patients who are incarcerated

          -  Patients who have a history or the presence at baseline of pulmonary interstitial
             disease or drug-related pneumonitis, or radiation pneumonitis

          -  Patients who have a known history of human immunodeficiency virus (HIV); testing not
             required in the absence of history

          -  Patients with history of clinically significant bleeding disorder or history of active
             significant gastrointestinal (GI) bleeding within 3 months of first dose of brigatinib

          -  Patients who have malabsorption syndrome or other GI illness or condition that could
             affect oral absorption of the study drug

          -  History of allergic or suspected hypersensitivity reactions attributed to compounds of
             similar chemical or biologic composition to brigatinib

          -  Patients with history of clinically significant atrial arrhythmias (requiring any
             anti-arrhythmic therapy or as determined by the treating physician) or any history of
             ventricular arrhythmias

          -  Patients who have significant, uncontrolled or active cardiovascular disease,
             including but not restricted to the following:

               -  Myocardial infarction (MI) within 6 months prior to first dose of brigatinib

               -  Unstable angina (UA) within 6 months prior to first use

               -  Decompensated congestive heart failure within 6 months prior to first dose

               -  Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months
                  prior to first dose

          -  Clinically significant, uncontrolled intercurrent illness including, but not limited
             to:

               -  Symptomatic or active infection requiring intravenous (IV) antibiotics

               -  Psychiatric illness and/or social situations that would limit compliance with
                  completion of study requirements

          -  Patients on medications known to be associated with torsades de pointes

          -  Patients who have uncontrolled hypertension; patients with hypertension should be
             under treatment on study entry to control blood pressure

          -  Patients who have received cytotoxic chemotherapy, investigational agents, or
             radiation within 14 days, except stereotactic radiosurgery (SRS) or stereotactic body
             radiosurgery

          -  Patients who have received monoclonal antibodies or had major surgery within 30 days
             of the first dose of brigatinib

          -  Patients who have not recovered (=< Common Terminology Criteria for Adverse Events
             [CTCAE] grade 1) from adverse events (with the exception of alopecia) due to agents
             administered more than 4 weeks earlier

          -  Patients with symptomatic CNS metastases that are neurologically unstable or require
             increasing dose of corticosteroids

          -  Patients with current spinal cord compression